Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Systemic treatment of cholangiocellular carcinoma in Germany – Results from the prospective national intersectoral cohort study JADE

Freiberg-Richter J, Uhlig J, von der Heyde E, Schröder J, Pereira PL, Hofmann WP, et al.
Onco Targets Ther. 2023;46 (Suppl.5)(V309):354

Link

Indikation: Leberkrebs, Liver Cancer / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
JADE
2023
Testing for and frequency of EGFR and ALK alterations in patients with early and locally advanced non-small cell lung cancer in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315)

Eberhardt WEE, Thomas M, Stuschke M, De Wit M, Seese B, Spring L, Andres-Pons A, Jaenicke M, Vahtrik O, Ludwig P, Hipper A, Hoffknecht P, von der Heyde E, Sebastian M, Gröschel A, Passlick B, Griesinger F

Link

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2023
First glance on outcome in routine care of patients with multiple myeloma in Germany – results from the MYRIAM registry

Reiser, M., von der Heyde, E., Dechow, T., Bürkle, D., Groschek, M., Kiewe, P., Hansen, T., Langer, C., Medinger, T., Jänicke, M., Potthoff, K., Engelhardt, M., Einsele, H., Knauf, W.

Download

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MYRIAM
2023
Genetische Tumor-Profile von Patienten mit oder ohne klinisches Ansprechen auf PD-(L)1-Antikörper-Behandlung in verschiedenen Tumor-Entitäten – Ein Biobank-Forschungsprojekt des INFINITY-Registers

Hillebrand LE, Vannier C, Matter M, Läubli H, Jermann PM, Sellmann L, Schröder J, Decker T, Schuler M, Zaiss M, Reiser M, Neise M, Grebhardt S, Wright PR, Woerner SM, Kasenda B, Potthoff K.

Download

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: DGHO / Journal:
INFINITY
2023
Risk score assessment in clinical routine including gene expression testing – Interim Results of the non-interventional study PERFORM evaluating Palbociclib in Combination with Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

Fietz T., Radosa J., Wilke J., Decker T., Petersen V., Deryal M., Knoblich, J., Losem, C., Rhein U., Schöttker B., Wrobel D., Cubas Cordova M., Buncke J., Frank, M., Woerner S. M., Adams, A., Lux, M. P., Bartsch R.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal:
PERFORM
2023
Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma

Kümmerl, L., Kraulich, M., Lesyuk, W., Binninger, A., Goebell, P.J., Kahlmeyer, A., 2023.

Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2023.06.011

Link

Indikation: Nierenzellkarzinom, Renal Cell Carcinoma / Veranstaltung: / Journal: Urologic Oncology
TNK
2023
Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma.

Kümmerl, L., Kraulich, M., Lesyuk, W., Binninger, A., Goebell, P.J., Kahlmeyer, A., 2023.

Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2023.06.011

Link

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Urologic Oncology
CARAT
2023
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.

Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D, Moorahrend E, Sauer A, Bruch HR, Liersch R, Nusch A, Vehling-Kaiser U, Welslau M, Grunewald R, Harich HD, Stephany M, Uhlig J, de Buhr R, Frank M, Hogrefe C, Marschner N, Potthoff K, Hartmann F, Reisländer T, Schwaner I.

Int J Cancer. 2023 Sep 15;153(6):1227-1240. doi: 10.1002/ijc.34603. Epub 2023 Jun 1.

Link

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: International Journal of Cancer
TACTIC
2023
Real-world Daten zur Erhaltungstherapie mit Durvalumab nach definitiver Strahlenchemotherapie bei Patienten mit Nicht-Kleinzelligem Lungenkarzinom in lokal fortgeschrittenen Stadien: Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

M. Stuschke, F. Griesinger, M. Thomas, A. Gröschel, P. Christopoulos, M. Reck, P. Ludwig, A. Hipper, L. Spring, A. Andres-Pons, M. Jänicke, S. Dörfel, M. Bendel, K. Kokowski, B. Passlick, M. Sebastian, W.E.E. Eberhardt.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: -
CRISP
2023
PCI in der metastasierten Situation beim SCLC in real world: Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

T. Gauler, R. Fischer, M. Reck, C. Grah, M. Heilmann, P. Ludwig, A. Hipper, N. Wetzel, T. Medinger, A. Binninger, M. Jänicke, P. Hoffknecht, W. Gleiber, F. Griesinger, M. Thomas, W. E. E. Eberhardt, C. F. Waller, M. Sebastian, 2023.

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DEGRO / Journal: -
CRISP
2023